Non-Coding RNAs in Myasthenia Gravis: From Immune Regulation to Personalized Medicine DOI Creative Commons
Nicola Iacomino, Maria Cristina Tarasco,

Alessia Berni

и другие.

Cells, Год журнала: 2024, Номер 13(18), С. 1550 - 1550

Опубликована: Сен. 14, 2024

Myasthenia gravis (MG) is an antibody-mediated autoimmune disorder characterized by altered neuromuscular transmission, which causes weakness and fatigability in the skeletal muscles. The etiology of MG complex, being associated with multiple genetic environmental factors. Over recent years, progress has been made understanding immunological alterations implicated disease, but exact pathogenesis still needs to be elucidated. A pathogenic interplay between innate immunity autoimmunity contributes intra-thymic development. Epigenetic changes are critically involved both adaptive immune response regulation. They can act as (i) pathological factors besides predisposition (ii) co-factors contributing disease phenotypes or patient-specific course/outcomes. This article reviews role non-coding RNAs (ncRNAs) epigenetic MG. Particular attention dedicated microRNAs (miRNAs), whose expression patients' thymuses circulating blood. long ncRNA (lncRNA) contribution MG, although not fully yet, also discussed. By summarizing most fast-growing findings on ncRNAs we highlight therapeutic potential these molecules for achieving regulation their value biomarkers development personalized medicine approaches improve care.

Язык: Английский

Exploiting regulatory T cells (Tregs): Cutting-edge therapy for autoimmune diseases DOI Creative Commons
Marwa Hassan, Mohamed Elzallat, Dina Mostafa Mohammed

и другие.

International Immunopharmacology, Год журнала: 2025, Номер 155, С. 114624 - 114624

Опубликована: Апрель 10, 2025

Regulatory T cells (Tregs) are a specialized subset of suppressive that essential for maintaining self-tolerance, regulating effector cells, managing microbial infections, preventing tumors, allergies, and autoimmune disorders, facilitating allograft transplantation. Disruptions in Treg function or abundance contribute to an imbalance between pathogenic protective immune diseases. Recently, one promising treatment strategy restore balance involves the selective expansion manipulation Tregs using low-dose IL-2 therapy, adoptive cell transfer, chimeric antigen receptor (CAR)-Treg approaches. have been shown increasing number research studies prevent even treat variety such as allergic diseases, transplant rejection, graft-versus-host disease. A thorough comprehension is anticipated provide clear prospects effective immunotherapy wide range This review provides overview biology, including their functions, mechanisms, phenotypic markers, well involvement disease settings. Furthermore, we discuss therapeutic potential different subpopulations translational applications

Язык: Английский

Процитировано

0
Emerging Mechanisms and Biomarkers Associated with T-Cells and B-Cells in Autoimmune Disorders DOI
Azhagu Madhavan Sivalingam

Clinical Reviews in Allergy & Immunology, Год журнала: 2025, Номер 68(1)

Опубликована: Фев. 11, 2025

Язык: Английский

Процитировано

0
Non-Coding RNAs in Myasthenia Gravis: From Immune Regulation to Personalized Medicine DOI Creative Commons
Nicola Iacomino, Maria Cristina Tarasco,

Alessia Berni

и другие.

Cells, Год журнала: 2024, Номер 13(18), С. 1550 - 1550

Опубликована: Сен. 14, 2024

Myasthenia gravis (MG) is an antibody-mediated autoimmune disorder characterized by altered neuromuscular transmission, which causes weakness and fatigability in the skeletal muscles. The etiology of MG complex, being associated with multiple genetic environmental factors. Over recent years, progress has been made understanding immunological alterations implicated disease, but exact pathogenesis still needs to be elucidated. A pathogenic interplay between innate immunity autoimmunity contributes intra-thymic development. Epigenetic changes are critically involved both adaptive immune response regulation. They can act as (i) pathological factors besides predisposition (ii) co-factors contributing disease phenotypes or patient-specific course/outcomes. This article reviews role non-coding RNAs (ncRNAs) epigenetic MG. Particular attention dedicated microRNAs (miRNAs), whose expression patients' thymuses circulating blood. long ncRNA (lncRNA) contribution MG, although not fully yet, also discussed. By summarizing most fast-growing findings on ncRNAs we highlight therapeutic potential these molecules for achieving regulation their value biomarkers development personalized medicine approaches improve care.

Язык: Английский

Процитировано

1